Effect of combination therapy of EPA and DHA on arterial stiffness in type 2 diabetic patients with hypertriglyceridemia

Effect of combination therapy of EPA and DHA on arterial stiffness in type 2 diabetic patients with hypertriglyceridemia - Effect of combination therapy of EPA and DHA on arterial stiffness in type 2 diabetic patients with hypertriglyceridemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011206

Enrollment

Registered

2013-07-22

Start date

2013-07-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertriglyceridemia with type 2 diabetes

Interventions

Switch from Epadel(1800mg/day) to rotoriga (2g/day) for 3 months. If the triglyceride level in the blood does not meet the management standards, will be increased to 4g/day from 2g/day the dose of ro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients in Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center with type 2 diabetes and hypertriglyceridemia, taking 1800mg/day of epadel.

Exclusion criteria

Exclusion criteria: Severe hypertriglyceridemia (TG>1000mg/dl) Familial hypercholesterolemia Patients with allergy to DHA

Design outcomes

Primary

Measure	Time frame
A change in CAVI(cardio-ankle vascular index)	—

Secondary

Measure	Time frame
Changes in lipid metabolic parameters (total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, apoprotein, LPL mass)	—

Countries

Japan

Contacts

Public ContactTakashi Yamaguchi

Toho University Sakura Medical Cneter Center of Diabetes, Endocrine and Metabolism

takashi_schecter@sakura.med.toho-u.ac.jp+81-43-462-8811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026